Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells
Background/Aim. Newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) tretaed with immunochemotherapy have durable remission and improved overall survival. It is important to identify high risk patients who may benefit from even more effective therapies. Methods. In a group of 50 newly...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Military Health Department, Ministry of Defance, Serbia
2009-01-01
|
Series: | Vojnosanitetski Pregled |
Subjects: | |
Online Access: | http://www.doiserbia.nb.rs/img/doi/0042-8450/2009/0042-84500909738P.pdf |
id |
doaj-ab6aaa9e547e4c6f874fe29afdc3990d |
---|---|
record_format |
Article |
spelling |
doaj-ab6aaa9e547e4c6f874fe29afdc3990d2020-11-24T23:11:37ZengMilitary Health Department, Ministry of Defance, SerbiaVojnosanitetski Pregled0042-84502009-01-0166973874310.2298/VSP0909738PPoor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cellsPeruničić-Jovanović MajaJaković LjubomirBogdanović AndrijaMarković OliveraČemerikić-Martinović VesnaMihaljević BiljanaBackground/Aim. Newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) tretaed with immunochemotherapy have durable remission and improved overall survival. It is important to identify high risk patients who may benefit from even more effective therapies. Methods. In a group of 50 newly diagnosed patients with DLBCL, treated with CHOP/R-CHOP (cyclophosphemide doxorubicine, vincristine, prednisone with or without rituximab) regimen, we analyzed the prognostic value of the expression of Ki67 and bcl-2 at diagnosis as well as other standard clinical parameters: International Prognostic Index (IPI), bulky disease, extranodal distribution and lactat dehydrogenase (LDH). Significance was tested according to response rate and overall survival. Results. Univariate survival analysis showed that high IPI had a statistically significant negative influence on overall and event free survival time (log rank, p < 0.01). The log rank test analysis signified that patients with a high proliferative fraction (Ki-67 > 60%) had a worse overall survival rate (OS5y) of 40% compared to those with low proliferation (Ki-67 < 60%) with OS5y of 80% (p < 0.01). There was a clear difference between bcl-2 positivity (treshold 50%) and the achievement of complete remission (66% vs 86% in patients with bcl-2 high and low levels respectively, p < 0.05). In survival analysis, patients with low bcl-2 expression had significantly higher OS5y - 68% compared to those with high bcl-2+ with OS5y 37% (p < 0.05). Multivariate analysis performed by Cox model revealed that IPI > 3, high Ki-67+, bcl-2 positivity had a significant independent prognostic value concerning overall survival (p < 0.05). Conclusion. An initial high IPI score associated with high Ki-67+ and bcl2+ could represent possible predictive factors of poor prognosis, which would help to identify a high risk subgroup of newly diagnosed DLBCL.http://www.doiserbia.nb.rs/img/doi/0042-8450/2009/0042-84500909738P.pdflymphoma, B-cellgenes, bcl-2Ki-67 antigenprognosisantineoplastic combined chemotherapy protocols |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Peruničić-Jovanović Maja Jaković Ljubomir Bogdanović Andrija Marković Olivera Čemerikić-Martinović Vesna Mihaljević Biljana |
spellingShingle |
Peruničić-Jovanović Maja Jaković Ljubomir Bogdanović Andrija Marković Olivera Čemerikić-Martinović Vesna Mihaljević Biljana Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells Vojnosanitetski Pregled lymphoma, B-cell genes, bcl-2 Ki-67 antigen prognosis antineoplastic combined chemotherapy protocols |
author_facet |
Peruničić-Jovanović Maja Jaković Ljubomir Bogdanović Andrija Marković Olivera Čemerikić-Martinović Vesna Mihaljević Biljana |
author_sort |
Peruničić-Jovanović Maja |
title |
Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells |
title_short |
Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells |
title_full |
Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells |
title_fullStr |
Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells |
title_full_unstemmed |
Poor outcome in patients with diffuse large B-cell lymphoma is associated with high percentage of bcl-2 and Ki 67-positive tumor cells |
title_sort |
poor outcome in patients with diffuse large b-cell lymphoma is associated with high percentage of bcl-2 and ki 67-positive tumor cells |
publisher |
Military Health Department, Ministry of Defance, Serbia |
series |
Vojnosanitetski Pregled |
issn |
0042-8450 |
publishDate |
2009-01-01 |
description |
Background/Aim. Newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) tretaed with immunochemotherapy have durable remission and improved overall survival. It is important to identify high risk patients who may benefit from even more effective therapies. Methods. In a group of 50 newly diagnosed patients with DLBCL, treated with CHOP/R-CHOP (cyclophosphemide doxorubicine, vincristine, prednisone with or without rituximab) regimen, we analyzed the prognostic value of the expression of Ki67 and bcl-2 at diagnosis as well as other standard clinical parameters: International Prognostic Index (IPI), bulky disease, extranodal distribution and lactat dehydrogenase (LDH). Significance was tested according to response rate and overall survival. Results. Univariate survival analysis showed that high IPI had a statistically significant negative influence on overall and event free survival time (log rank, p < 0.01). The log rank test analysis signified that patients with a high proliferative fraction (Ki-67 > 60%) had a worse overall survival rate (OS5y) of 40% compared to those with low proliferation (Ki-67 < 60%) with OS5y of 80% (p < 0.01). There was a clear difference between bcl-2 positivity (treshold 50%) and the achievement of complete remission (66% vs 86% in patients with bcl-2 high and low levels respectively, p < 0.05). In survival analysis, patients with low bcl-2 expression had significantly higher OS5y - 68% compared to those with high bcl-2+ with OS5y 37% (p < 0.05). Multivariate analysis performed by Cox model revealed that IPI > 3, high Ki-67+, bcl-2 positivity had a significant independent prognostic value concerning overall survival (p < 0.05). Conclusion. An initial high IPI score associated with high Ki-67+ and bcl2+ could represent possible predictive factors of poor prognosis, which would help to identify a high risk subgroup of newly diagnosed DLBCL. |
topic |
lymphoma, B-cell genes, bcl-2 Ki-67 antigen prognosis antineoplastic combined chemotherapy protocols |
url |
http://www.doiserbia.nb.rs/img/doi/0042-8450/2009/0042-84500909738P.pdf |
work_keys_str_mv |
AT perunicicjovanovicmaja pooroutcomeinpatientswithdiffuselargebcelllymphomaisassociatedwithhighpercentageofbcl2andki67positivetumorcells AT jakovicljubomir pooroutcomeinpatientswithdiffuselargebcelllymphomaisassociatedwithhighpercentageofbcl2andki67positivetumorcells AT bogdanovicandrija pooroutcomeinpatientswithdiffuselargebcelllymphomaisassociatedwithhighpercentageofbcl2andki67positivetumorcells AT markovicolivera pooroutcomeinpatientswithdiffuselargebcelllymphomaisassociatedwithhighpercentageofbcl2andki67positivetumorcells AT cemerikicmartinovicvesna pooroutcomeinpatientswithdiffuselargebcelllymphomaisassociatedwithhighpercentageofbcl2andki67positivetumorcells AT mihaljevicbiljana pooroutcomeinpatientswithdiffuselargebcelllymphomaisassociatedwithhighpercentageofbcl2andki67positivetumorcells |
_version_ |
1725603620560306176 |